Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

Timeline

Start

2020-06-11

Primary completion

2024-07

Completion

2024-10

Outcome

Outcome not reported

Stopped: “Sponsor ceasing all operations due to company's shut down”

Drugs

Indications